Media headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.7865595705862 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Beholding Stocks:- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Market Breaking Point (press release) (journalfinance.net)
- Notable Stocks in Focus: Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH), Hersha Hospitality Trust, (NYSE: HT … – Stocks In The News (press release) (tradingnewsnow.com)
- Is the Stock Safe to Invest?: Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) – Alpha Beta Stock (alphabetastock.com)
- Beta Factor in Focus – Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH) – Stock Watch (stocksnewstimes.com)
- Hot Stock of the Day – Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH) – Stock Watch (stocksnewstimes.com)
Aurinia Pharmaceuticals (AUPH) traded up $0.06 during trading hours on Friday, reaching $5.82. 900,952 shares of the company traded hands, compared to its average volume of 1,731,965. Aurinia Pharmaceuticals has a 1 year low of $2.02 and a 1 year high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. equities analysts predict that Aurinia Pharmaceuticals will post -1.01 earnings per share for the current year.
Several research firms recently commented on AUPH. HC Wainwright reiterated a “buy” rating and set a $12.00 target price (up from $10.00) on shares of Aurinia Pharmaceuticals in a research note on Monday, October 30th. Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 24th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Leerink Swann upped their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $10.79.
COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals (AUPH) Earns News Sentiment Score of 0.16” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/05/aurinia-pharmaceuticals-auph-earns-news-sentiment-score-of-0-16.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
What are top analysts saying about Aurinia Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aurinia Pharmaceuticals Inc and related companies.